Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A global network of scientific, medical and research trial collaborators works together on COPCOV, the MORU-led, Oxford-supported study to test if hydroxychloroquine or chloroquine can prevent COVID-19. 

As vaccines begin to roll out, finding drugs that prevent COVID-19 is more important than ever: It may be mid-2022 before there are enough COVID-19 vaccines for the 7.5 billion people on this planet. Scientifically proving that hydroxychloroquine provides even a small health benefit could save thousands of lives before vaccines become widely available, and COVID-19 brought under control. Understanding whether these drugs can effectively prevent COVID-19 infection would also support global preparedness for future potential emerging viral threats.

COPCOV has recruited participants from sites in Benin, Côte d’Ivoire, Indonesia, Kenya, Mali, Nepal, Pakistan, Zambia, Thailand, Niger and the UK. Preliminary study results are expected early Q2 2022.

Principal Investigators


Trial Researchers

There are no team members found
There are no team members found